In this roundtable discussion, Vincent Ma, MD, Associate Professor of Medicine at the University of Wisconsin School of Medicine and Public Health and medical oncologist at UW Carbone Cancer Center; Krista Rubin, MS, FNP-BC, Nurse Practitioner at Massachusetts General Cancer Center; and Dan Wellner, PharmD, BCOP, Oncology Clinical Pharmacist at UW Health, examine the clinical benefits and limitations of subcutaneous immune checkpoint inhibitors. The panel explores patient selection, efficacy and safety considerations, and the practical challenges of integrating subcutaneous immunotherapy into clinical practice.
Key Topics Discussed
Efficacy and Clinical Outcomes
- How do the efficacy and pharmacokinetic profiles of subcutaneous immune checkpoint inhibitors compare with their IV counterparts?
- What clinical evidence supports the use of subcutaneous formulations?
Safety and Tolerability
- How do the safety and tolerability profiles of subcutaneous and IV formulations compare?
- What are the considerations for managing injection-site reactions, hypersensitivity reactions, and immune-related adverse events?
- What monitoring protocols should be maintained when transitioning patients to subcutaneous therapy?
Operational Considerations
- What are the advantages and challenges of integrating subcutaneous immune checkpoint inhibitors into oncology practice?
- What institutional workflow modifications are required for subcutaneous administration?
- How do subcutaneous formulations affect pharmacy preparation, compounding efficiency, and hazardous drug handling?
- What are the implications for infusion center capacity, chair time, and resource utilization?
- How do formulary restrictions, reimbursement, and prior authorization requirements influence adoption?
- What dosing differences and medication safety considerations must be addressed when transitioning between IV and subcutaneous formulations?
Patient Selection and Treatment Optimization
- Which clinical scenarios favor subcutaneous administration over IV therapy?
- What patient characteristics or treatment-related factors may limit the suitability of subcutaneous formulations?
- How do concurrent therapies, treatment setting, and venous access influence administration route selection?
- What considerations guide the use of subcutaneous checkpoint inhibitors in maintenance and adjuvant treatment settings?